7:40 AM ET
10-Q
Financial Results
▶ Call
Intensity Therapeutics Q3 2026 Results: Net Loss of $3.54M, Loss Widens
Intensity Therapeutics reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to $8.6 million in the prior year period. The company's cash position decreased to $8.5 million from $11.9 million at year-end 2025, primarily due to ongoing research and development expenses for its lead drug candidate, INT230-6.
- Key figure
- Net loss $3.54M